JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pollak, R.
Right arrow Articles by Billstein, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pollak, R.
Right arrow Articles by Billstein, S. A.
Journal of the American Podiatric Medical Association Volume 91 Number 3 127-131 2001
Copyright © 2001 American Podiatric Medical Association

Efficacy of Terbinafine for Toenail Onychomycosis

A Multicenter Trial of Various Treatment Durations

Richard Pollak, DPM, MS* and Stephan A. Billstein, MD, MPH{dagger}

* Private practice, 8042 Wurzbach Rd, Ste 525, San Antonio, TX 78229.
{dagger} Executive Director, Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, NJ.

Abstract

The efficacy of terbinafine (250 mg/day) in the treatment of toenail onychomycosis was evaluated in a large open-label, multicenter trial of 12, 18, and 24 weeks of therapy. All 1,534 patients had onychomycosis, confirmed by either positive potassium hydroxide (KOH) wet mount, positive fungal culture, or both, and all received at least 12 weeks of treatment. Treatment was continued for an additional 6 or 12 weeks, depending on the extent of the disease at follow-up. Mycologic cure rates (negative culture plus negative KOH) at week 72 were 72.1% in the 12-week treatment group, 72.5% in the 18-week group, and 77.0% in the 24-week group. In all groups, clinical cure rates were higher at week 72 than at week 48: 49.5% of the 12-week group, 49.2% of the 18-week group, and 44.6% of the 24-week group experienced clinical cure by the end of the study. Both mycologic and clinical recurrence rates were low in all treatment groups at the 72-week assessment. The results of this study confirm the efficacy of terbinafine in the treatment of toenail onychomycosis as demonstrated in previous registration and large-scale clinical trials. (J Am Podiatr Med Assoc 91(3): 127-131, 2001)




This article has been cited by other articles:


Home page
 J. Am. Podiatr. Med. Assoc.Home page
M. B. Jennings, R. Pollak, L. B. Harkless, F. Kianifard, and A. Tavakkol
Treatment of Toenail Onychomycosis with Oral Terbinafine Plus Aggressive Debridement: IRON-CLAD, a Large, Randomized, Open-Label, Multicenter Trial.
J Am Podiatr Med Assoc, November 1, 2006; 96(6): 465 - 473.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
E. M. Warshaw
Evaluating Costs for Onychomycosis Treatments: A Practitioner's Perspective
J Am Podiatr Med Assoc, January 1, 2006; 96(1): 38 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
A. K. Gupta
Treatment of Dermatophyte Toenail Onychomycosis in the United States: A Pharmacoeconomic Analysis
J Am Podiatr Med Assoc, May 1, 2002; 92(5): 272 - 286.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Podiatric Medical Association.